Palatin Technologies, Inc. — Form 10-Q summary
Reporting period: Three months ended September 30, 2013 (Palatin’s fiscal first quarter of fiscal 2014). The filing is unaudited. Palatin is a development-stage biopharmaceutical company; its primary clinical program is bremelanotide for female sexual dysfunction (FSD).
Financial performance and position
| Metric | Quarter ended September 30, 2013 | Comparable 2012 period |
|---|---|---|
| Revenue | $0 | $3,806 |
| Research and development expense | $3.45 million | $2.34 million |
| General and administrative expense | $1.04 million | $1.06 million |
| Net loss | $4.49 million | $10.45 million |
| Basic and diluted loss per share | $0.04 | $0.15 |
| Net cash used in operating activities | $2.05 million | $4.73 million |
- R&D expense increased about 47%, primarily reflecting higher spending across development programs. Management said most program-specific spending was associated with bremelanotide.
- The prior-year net loss included a $7.07 million non-cash increase in the fair value of warrants; excluding that unusual item, the year-over-year loss comparison is substantially different.
- At September 30, cash and cash equivalents were $18.59 million and short-term investments were $3.75 million, totaling about $22.33 million. Current liabilities were $4.20 million; total liabilities were $4.22 million. Capital lease obligations were $14,068, and the filing reports no material borrowing debt.
- Stockholders’ equity was $18.67 million, down from $22.98 million at June 30, 2013. Accumulated deficit was $264.59 million.
- Cash and cash equivalents decreased $0.58 million during the quarter. Investing activities provided $1.49 million, mainly from investment maturities; financing activities used $31,055. The filing does not present a meaningful operating margin given the absence of revenue and ongoing development spending.
Changes, outlook, and risks
- Operating cash use was lower than in the prior-year quarter, partly because Palatin received a $1.0 million non-refundable option fee for negotiations concerning a potential bremelanotide license in a territory outside North America, and partly because of a payment deferral. The fee was recorded as unearned revenue, not recognized revenue; the option could expire in the first quarter of calendar 2014 if not exercised, subject to contingencies.
- Management planned to submit complete protocols for pivotal bremelanotide Phase 3 studies to the FDA and expected to start trials in the first quarter of calendar 2014. The proposed program includes two pivotal trials; management estimated it would cost at least $78 million and take 15–18 months from first patient dosing through database lock.
- Palatin said existing capital was expected to fund planned operations—including Phase 3 preparation, but not patient enrollment—through at least calendar 2014. It does not intend to begin enrollment without adequate funds or commitments to complete the program and expects to seek funding through collaboration, equity, debt, or other sources.
- Management expects significant losses to continue. Profitability depends on successful development, clinical results, regulatory approval, commercialization, and access to additional capital. Development timing, costs, and outcomes remain uncertain; AstraZeneca’s obesity-related program is also subject to the partner’s evaluation and continued development decisions.
- Other programs include PL-3994 and preclinical melanocortin receptor-1 candidates. Palatin intended to select potential MC1R development candidates and indications during the fiscal year, subject to successful studies.
- The company reported no current legal proceedings and no material changes to risk factors disclosed in its prior Form 10-K. Management concluded disclosure controls were effective at September 30, 2013.
Important facts for investors to verify
- Whether Palatin secures funding or a collaboration sufficient to cover the estimated $78 million Phase 3 program before enrollment begins.
- Whether the anticipated FDA protocol submissions and planned Phase 3 start occur on schedule, and the resulting trial design, cost, and timeline.
- The status and terms of the potential territorial license associated with the $1.0 million option fee, including whether a definitive agreement is reached.
- Quarterly cash burn, accrued liabilities, and remaining cash runway as development spending changes.
- Potential dilution and warrant-related share effects: the filing reports 39.19 million common shares outstanding at September 30, while weighted-average shares used for loss per share were 106.61 million, reflecting the filing’s treatment of nominal-exercise warrants.